Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

ope.

UVIDEM has been administered to 143 patients in clinical development. Patient enrollment has been completed in three other Phase 2 clinical trials including individuals with resected stage 2 or 3 melanoma and individuals with metastatic melanoma. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma.

IDM-2101

The Company announced updated results in November 2007 from its Phase 2 trial in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients. Updated one-year survival in patients treated with IDM-2101 was 60 percent, compared to 49 percent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group.

Based on this encouraging survival trend, the Company has continued to work with outside consultants and clinical advisors to develop a next-step clinical plan for IDM-2101. The Company expects to have the clinical plan completed by the end of 2007.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

At September 30, 2007 the Company had cash and cash equivalents of $33.2 million.

For more information about the Company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release and the presentation described in this press release include forward
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... segment of the $13 billion global cardiac rhythm ... Kalorama Information.  Kalorama found that Medtronic, St. Jude ... Medical) command 80% of this market segment. The ... Management Device Markets , uses 2015 as a ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, ... announced a peer-reviewed publication of the results of ... RGN-259 (RegeneRx,s preservative-free eye drops) for the treatment ... adverse environment (CAE ® ) model.  The exploratory ... results, which were previously disseminated by the Company ...
(Date:5/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3rthk2/latest ... "Latest Regulations on Pharmaceutical International Multi-Center Clinical Trials ... This is first time in history, Chinese ... multi-center clinical trials of drugs in ... implemented on March 1, 2015. The guidance provides ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... Recovery Systems announced today that it has been awarded ... the group purchasing unit of the Premier healthcare alliance, ... its more than 75,000 healthcare member facilities. After hearing ... LRS Director of Marketing commented, " We are very ...
... "Simple Inspirations," a new contest, sponsored by Bayer ... diagnosed patients by sharing their most inspirational thoughts about ... is to enrich the lives of everyone who has ... -- and to demonstrate that people with diabetes can ...
Cached Medicine Technology:Life Recovery Systems Awarded Contract With Premier for Patient Temperature Management 2Life Recovery Systems Awarded Contract With Premier for Patient Temperature Management 3Nick Jonas and Bayer HealthCare Announce "Simple Inspirations" Contest to Motivate and Support Those Newly Diagnosed with Diabetes 2Nick Jonas and Bayer HealthCare Announce "Simple Inspirations" Contest to Motivate and Support Those Newly Diagnosed with Diabetes 3
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... allow them to take pressure measurements in patients’ bladder ... The doctor usually orders it if they have reported ... (OAB). , Women’s Excellence in Bladder Control ... with unwanted urinary leakage or problems with overall control ...
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin markers ... to pin point locations on a map, to indicate prices or ... users to choose from 30 simplistic presets with geometric design elements ... editors can easily manipulate ProPin presets as a whole. Pixel ... , Using ProPin is easy, simply drag a preset into the ...
(Date:5/24/2015)... CA (PRWEB) May 24, 2015 ... clear indicator that the single best option for avoiding ... reveals that fitness level was the single most powerful ... for variables such as diabetes and family history of ... of maintaining lifelong heart and lung fitness. , The ...
(Date:5/23/2015)... Diego, CA (PRWEB) May 23, 2015 ... especially small businesses, are finding it increasingly difficult to ... businesses which fail to provide adequate insurance for employees ... for businesses been such an integral part of a ... more affordable healthcare for businesses, Online USA Doctors has ...
(Date:5/23/2015)... 23, 2015 A live auction will be ... hospitals, surgery centers and other medical facilities around the United ... endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... and Thursday, May 28 starting at 9:00am CDT each day. ... N. 25th Avenue, Melrose Park, IL 60160. Anyone can ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... of millions of dollars annually in medical care, suggesting ... improve outcomes but also save substantial amounts of money, ... nearly 150,000 people in six states. , "Substance abuse ... think," said Robin E. Clark, PhD, associate professor of ...
... to malignancy, study suggests , , MONDAY, Jan. 5 (HealthDay ... hormone replacement therapy may face an increased risk of ... suggests. , Interestingly, obese women who have used hormone ... face increased risk for this type of malignancy. , ...
... National Hot Tea Month, the Height of the Cold and Flu ... and is also the height of the dreaded "cold and flu ... Americans affected by the cold and flu this year, which leads ... one do to avoid the cold and flu?The CDC strongly recommends ...
... During the Same Study Period, According To New ... Arlington Medical Resources (AMR), a provider of ... imaging industries, finds that the number of micro-bubble ... increased by more than 50 percent, to nearly ...
... Jan. 5 Vocollect Healthcare Systems, Inc.,announces ... Louisiana, is,deploying AccuNurse(R) voice-assisted care in four ... part of its implementation, Central Control will,begin ... in the next two,largest facilities -- Camelot ...
... of a Survey Kiosk buyer,s guide. The guide explains how ... their customers by capturing real-time in-store customer feedback. , ... ... 2009 -- Opinionmeter International, developer of the award winning customer ...
Cached Medicine News:Health News:Substance abuse adds millions to Medicaid's total health care costs 2Health News:Substance abuse adds millions to Medicaid's total health care costs 3Health News:Obesity Linked to Ovarian Cancer 2Health News:Obesity Linked to Ovarian Cancer 3Health News:Flu Season is Tea Time 2Health News:Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008 2Health News:Micro-Bubble Echo Contrast Procedures Continue to Rebound in October 2008 3Health News:Central Control is First Louisiana-Based Organization to Deploy Voice-Assisted Care 2Health News:Central Control is First Louisiana-Based Organization to Deploy Voice-Assisted Care 3Health News:Guide for Using Survey Kiosks for Instant Customer Feedback Sponsored by Opinionmeter 2Health News:Guide for Using Survey Kiosks for Instant Customer Feedback Sponsored by Opinionmeter 3
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
Medicine Products: